PCSK9 and coronary artery disorder: Of interest, NLRP3 inflammasome and, as a result, IL-1β, are also partly modulating the secretion of proprotein convertase subtilisin/kexin type 9 (PCSK9), a well-established therapeutic target in CAD [32].